12390 EL CAMINO REAL, SAN DIEGO, CA
REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
Annual Meeting of Stockholders Held; Three Proposals Voted On
Appoints Darren Snellgrove as Chief Financial Officer
Bylaw Amendments - Halozyme Therapeutics Revises Director Removal Policy
Annual Report to Security Holders
Appoints David Ramsay as Interim Chief Financial Officer
Financial Results, Press Release
Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence
Amended Tender Offer Statement by Third Party